| Recruiting | A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to S Moderate to Severe Vernal Keratoconjunctivitis | Phase 2 | 2026-03-24 |
| Recruiting | Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression Myopia | Phase 2 | 2026-01-21 |
| Not Yet Recruiting | Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Dry Eye Disease (DED) | — | 2025-12-15 |
| Not Yet Recruiting | Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery. Eyelid; Wound | — | 2025-11-15 |
| Recruiting | New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye Disease (DED) | Phase 4 | 2025-10-21 |
| Recruiting | Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP® Adherence to Glaucoma Therapy | — | 2025-09-19 |
| Recruiting | Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis | Phase 3 | 2025-06-04 |
| Completed | Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dr Dry Eye Disease (DED) | — | 2025-01-27 |
| Recruiting | Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind | Phase 2 | 2024-12-11 |
| Completed | Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome. Dry Eye Syndrome | N/A | 2024-09-17 |
| Completed | Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients Glaucoma, Ocular Hypertension | Phase 2 | 2024-08-05 |
| Completed | Performance and Safety of T2769 in DED Dry Eye | N/A | 2023-10-02 |
| Completed | Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms. Dry Eye | N/A | 2023-08-15 |
| Completed | Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drop Healthy Volunteers | Phase 1 | 2023-02-27 |
| Completed | Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers Healthy Volunteers | N/A | 2022-10-17 |
| Active Not Recruiting | Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | 2022-07-05 |
| Completed | Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypert Glaucoma, Ocular Hypertension | Phase 3 | 2022-06-22 |
| Terminated | Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind | Phase 2 / Phase 3 | 2021-12-15 |
| Terminated | Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in E Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind | Phase 2 / Phase 3 | 2021-12-08 |
| Terminated | An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmento Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | 2021-09-16 |
| Completed | Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Pa Ocular Hypertension Glaucoma | Phase 3 | 2021-03-26 |
| Completed | Macula Evolution in Patients With AMD Taking Oral Food Supplementation Age Related Macular Degeneration | N/A | 2021-01-13 |
| Completed | Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma Glaucoma | N/A | 2020-09-25 |
| Completed | Gastrointestinal Tolerance Assessment of T2309 Healthy Adult Subjects | N/A | 2020-07-15 |
| Completed | Efficacy and Tolerability of Blephademodex Wipes Demodex Blepharitis | N/A | 2019-09-11 |
| Terminated | Extension Study to Study PQ-110-001 (NCT03140969) Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis | Phase 1 / Phase 2 | 2019-05-13 |
| Completed | Efficacy of T2259 in DED Dry Eye Syndromes | N/A | 2019-04-24 |
| Completed | Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days Dry Eye | — | 2019-04-01 |
| Completed | Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients Ocular Hypertension, Glaucoma | Phase 3 | 2018-11-23 |
| Completed | Efficacy, Safety of T2769 in Dry Eye Disease Dry Eye Syndrome | N/A | 2018-09-01 |
| Completed | Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) Leber's Congenital Amaurosis | Phase 1 / Phase 2 | 2017-10-16 |
| Completed | Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Keratoconus | N/A | 2016-12-01 |
| Terminated | Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye S Dry Eye Syndrome | N/A | 2015-02-01 |
| Completed | Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients Open Angle Glaucoma, Ocular Hypertension | Phase 3 | 2014-12-01 |
| Completed | Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome Dry Eye Syndrome | Phase 3 | 2013-12-01 |
| Completed | Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Primary Open Angle Glaucoma, Ocular Hypertension | Phase 4 | 2013-12-01 |
| Completed | Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Cor Keratitis, Corneal Ulcer | Phase 3 | 2013-02-01 |
| Completed | Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice Palpebral Pathologies, Ocular Surface Disease, Meibomian Gland Dysfunction | — | 2012-03-01 |
| Completed | Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Synd Dry Eye Syndromes | Phase 3 | 2012-03-01 |
| Completed | Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery Cataract | Phase 3 | 2011-06-01 |
| Completed | Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Se Seasonal Allergic Conjunctivitis | Phase 2 | 2011-04-01 |
| Completed | Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms o Allergic Conjunctivitis | Phase 4 | 2010-10-01 |
| Completed | Warming Efficiency of Warm Compresses Versus BLEPHASTEAM® in Eyelid Therapy Eyelid Diseases | Phase 1 | 2010-09-01 |
| Completed | Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases Eyelid Diseases | Phase 4 | 2010-06-01 |
| Completed | Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases Eyelid Diseases | Phase 4 | 2010-05-01 |
| Completed | Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis Blepharitis | Phase 2 | 2010-03-01 |
| Completed | Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients Glaucoma | Phase 3 | 2009-09-01 |
| Completed | Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis Acute Adenoviral Keratoconjunctivitis | Phase 2 | 2009-03-01 |
| Completed | Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Purulent Bacterial Conjunctivitis | Phase 3 | 2008-12-01 |
| Completed | Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients. Glaucoma | Phase 4 | 2008-07-01 |
| Completed | Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed P Primary Open Angle Glaucoma | Phase 2 | 2008-06-01 |
| Completed | Efficacy of T1675 Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye Syndrome Dry Eye Syndromes | Phase 2 | 2004-11-01 |
| Completed | Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctiviti Conjunctivitis, Bacterial | Phase 3 | 2004-05-01 |
| Completed | Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trac Trachoma | Phase 3 | 2004-01-01 |
| Completed | Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers Eye Infections, Bacterial | Phase 1 | 2003-02-01 |
| Completed | Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers Eye Infections, Bacterial | Phase 1 | 2002-10-01 |
| Completed | Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers Eye Infections, Bacterial | Phase 1 | 2002-05-01 |
| Completed | Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunt Eye Infections, Bacterial | Phase 1 | 2002-03-01 |
| Completed | Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers Eye Infections, Bacterial | Phase 1 | 2002-02-01 |
| Completed | Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Keratoconjunctivitis, Vernal | Phase 4 | 2001-04-01 |
| Completed | Clinical Safety Study on an Eyelid Warming Device to Evaluate the Eyelid and Cornea Temperature in Healthy Vol Eyelid Diseases | Phase 1 | — |
| Withdrawn | Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops Vials Assess the Patient Feeling About the Handiness of Two Different Vials Used to Deliver Both, Unpreserved Hyaluronic Eye Drops | N/A | — |